Profusa Inc. said it will not proceed with its planned public offering and intends to file a post-effective amendment to withdraw its Form S-1 registration statement (No. 333-293451), originally filed Feb. 13, 2026. The company said it reevaluated near-term capital needs following changes in projected 2026 revenue and its Mayo Clinic collaboration, and determined a $15 million offering is not required to achieve near-term revenue projections. Profusa said it will pursue a smaller, more focused offering to support projected Europe Lumee Oxygen product revenue starting in Q2 2026 and to invest in its Mayo collaboration aimed at accelerating Lumee Oxygen in the U.S. and developing additional continuous oxygen monitoring products. The company said no securities were sold in connection with the offering described in the registration statement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602270915PRIMZONEFULLFEED9662871) on February 27, 2026, and is solely responsible for the information contained therein.